 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Onbrez, Arcapta |
| AHFS/Drugs.com | International Drug Names |
| License data | |
| Pregnancy category |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.218.577 |
| Chemical and physical data | |
| Formula | C24H28N2O3 |
| Molar mass | 392.499 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist[5] developed byNovartis. It needs to be taken only once a day,[6] unlike the related drugsformoterol andsalmeterol. It is licensed only for the treatment ofchronic obstructive pulmonary disease (COPD) (long-term data in patients withasthma are thus far lacking). It is delivered through adry powder inhaler.[7]
A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists.[8]
| Receptor | Ki |
|---|---|
| β1 | 6.21 |
| β2 | 7.36 |
| β3 | 5.48 |
It was approved by theEuropean Medicines Agency (EMA) under the brand name Onbrez Breezhaler on November 30, 2009,[10] and by theUnited States Food and Drug Administration (FDA), under the brand name Arcapta Neohaler, on July 1, 2011.[11][12] In 2016, Novartis licensed its U.S. commercial rights for Arcapta Neohaler toSunovion Pharmaceuticals.[13]